PDS Biotechnology (NASDAQ:PDSB) Given "Buy" Rating at HC Wainwright

PDS Biotechnology (NASDAQ:PDSB - Get Free Report)'s stock had its "buy" rating reiterated by research analysts at HC Wainwright in a note issued to investors on Tuesday,Benzinga reports. They presently have a $13.00 price target on the stock.

Separately, Wall Street Zen cut shares of PDS Biotechnology from a "hold" rating to a "sell" rating in a report on Saturday, June 14th.

PDS Biotechnology Stock Down 5.7%

PDSB stock opened at $1.33 on Tuesday. The company has a market capitalization of $60.79 million, a price-to-earnings ratio of -1.41 and a beta of 1.27. The company has a current ratio of 2.33, a quick ratio of 2.33 and a debt-to-equity ratio of 0.29. PDS Biotechnology has a 52 week low of $0.85 and a 52 week high of $4.42. The firm's 50-day moving average is $1.46 and its two-hundred day moving average is $1.42.

PDS Biotechnology (NASDAQ:PDSB - Get Free Report) last issued its quarterly earnings results on Wednesday, May 14th. The company reported ($0.21) earnings per share for the quarter, beating analysts' consensus estimates of ($0.25) by $0.04. On average, analysts forecast that PDS Biotechnology will post -1.2 earnings per share for the current fiscal year.

Hedge Funds Weigh In On PDS Biotechnology

Institutional investors have recently bought and sold shares of the stock. Marshall Wace LLP lifted its position in PDS Biotechnology by 38.4% in the 4th quarter. Marshall Wace LLP now owns 39,024 shares of the company's stock worth $64,000 after buying an additional 10,837 shares in the last quarter. Raymond James Financial Inc. bought a new stake in shares of PDS Biotechnology in the fourth quarter valued at approximately $26,000. Jane Street Group LLC bought a new stake in shares of PDS Biotechnology in the fourth quarter valued at about $58,000. Blair William & Co. IL increased its stake in PDS Biotechnology by 29.4% during the fourth quarter. Blair William & Co. IL now owns 157,500 shares of the company's stock valued at $257,000 after acquiring an additional 35,757 shares during the period. Finally, Two Sigma Investments LP lifted its position in shares of PDS Biotechnology by 273.5% in the 4th quarter. Two Sigma Investments LP now owns 65,732 shares of the company's stock worth $107,000 after acquiring an additional 48,132 shares during the period. Hedge funds and other institutional investors own 26.84% of the company's stock.

About PDS Biotechnology

PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, and human papillomavirus associated malignancies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.